Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | JAK1 | P23458 | 1/20 | 0.57 |
| ▸ | PTPRB | P23467 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960832 | 0.85 | STS (0.52) | STSJAK2JAK1PTPRBPTPN11 | |
| SCHEMBL3012474 | 0.84 | JAK2 (0.62) | STSJAK2JAK1PTPRBPTPN11 | |
| SCHEMBL803527 | 0.83 | JAK2 (0.74) | STSJAK2JAK1PTPRBPTPN11 | |
| SCHEMBL28746678 | 0.83 | CA2 (0.49) | MEN1KMT2A | |
| SCHEMBL618193 | 0.81 | JAK2 (0.59) | STSJAK2JAK1PTPRBPTPN11 | |
| SCHEMBL29243644 | 0.80 | JAK2 (0.66) | STSJAK2JAK1PTPRBPTPN11 | |
| SCHEMBL29243776 | 0.80 | JAK2 (0.66) | STSJAK2JAK1PTPRBPTPN11 | |
| SCHEMBL3617960 | 0.80 | JAK2 (0.55) | STSJAK2JAK1PTPRBPTPN11 | |
| SCHEMBL7608032 | 0.80 | GPR119 (0.52) | STSGPR119MEN1KMT2AUSP30 | |
| SCHEMBL13853353 | 0.80 | OPRM1 (0.60) | STSJAK2JAK1PTPRBPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042899-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | LEHR PHILIPP | 2009-02-12 | — | — | US | disclosed |
| US-7439362-B2 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2008-10-21 | — | — | US | disclosed |
| US-20060052393-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2006-03-09 | — | — | US | disclosed |
| EP-1492782-A1 | PIPERAZINYL- OR PIPERIDINYLAMINE-SULFAMIC ACID AMIDES AS INHIBITORS OF STEROID SULFATASE | Novartis AG (CH) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082842-A1 | PIPERAZINYL- OR PIPERIDINYLAMINE-SULFAMIC ACID AMIDES AS INHIBITORS OF STEROID SULFATASE | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042899-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | STS, SULT2A1, ARSA | STS 1/4885JAK2 1860/4885JAK1 3209/4885 |
| US-20060052393-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | STS, SELENOI, SULT2A1 | STS 1/4885JAK2 1675/4885JAK1 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.